Last reviewed · How we verify
BIA 2-093
At a glance
| Generic name | BIA 2-093 |
|---|---|
| Also known as | ESL, Eslicarbazepine acetate, Eslicarbazepine acetate, ESL, Eslicarbazepine Acetate |
| Sponsor | Bial - Portela C S.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Anti-epileptogenic Effects of Eslicarbazepine Acetate (PHASE2)
- A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate (PHASE1)
- Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization (PHASE1)
- A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers (PHASE1)
- Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine (PHASE1)
- Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers (PHASE1)
- The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin (PHASE1)
- Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIA 2-093 CI brief — competitive landscape report
- BIA 2-093 updates RSS · CI watch RSS
- Bial - Portela C S.A. portfolio CI